SCHEMBL24254507

SCHEMBL24254507

Cc1ccc(SNc2ccccc2)cc1NC(=O)Cc1ccc(Cl)c(Cl)c1

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 6/20 0.48
KMT2A Q03164 6/20 0.48
LMNA P02545 4/20 0.48
MAPT P10636 3/20 0.48
HTT P42858 3/20 0.48
L3MBTL1 Q9Y468 2/20 0.48
ALDH1A1 P00352 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
KCNQ2 O43526 1/20 0.47
GAA P10253 2/20 0.45
MCOLN3 Q8TDD5 1/20 0.45
TRPV1 Q8NER1 1/20 0.44
HPGD P15428 1/20 0.44
KDM4E B2RXH2 1/20 0.43
CLK1 P49759 1/20 0.43
POLB P06746 1/20 0.43
PARP14 Q460N5 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24254550 0.86 HPGD (0.46) MEN1KMT2ALMNAMAPTHTT
SCHEMBL24254521 0.86 L3MBTL1 (0.52) MEN1KMT2ALMNAMAPTL3MBTL1
SCHEMBL24254575 0.80 MAPT (0.53) MEN1KMT2ALMNAMAPTHTT
SCHEMBL24254503 0.78 MGAT2 (0.54) MEN1KMT2ALMNAMAPTHTT
SCHEMBL24254623 0.76 KCNQ2 (0.53) MEN1KMT2ALMNAMAPTHTT
SCHEMBL24254494 0.74 EPHX2 (0.55) LMNAMAPTHTTALDH1A1SMN1; SMN2
SCHEMBL24254499 0.73 LMNA (0.53) MEN1KMT2ALMNAMAPTHTT
SCHEMBL26188045 0.73 ALDH1A1 (0.57) MEN1KMT2ALMNAMAPTHTT
SCHEMBL24254502 0.70 ALDH1A1 (0.66) MEN1KMT2ALMNAMAPTHTT
SCHEMBL24254523 0.70 HPGD (0.59) MEN1KMT2ALMNAMAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022035804-A1 SUBSTITUTED 3-AMINO-4-METHYLBENZENESULFONAMIDES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-02-17 WO disclosed